title: Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients.
abstract: BACKGROUND
  Stored serum from clinical trial cases undergoing ProstaScint (CYT-356) scanning were available for Prostate Specific Membrane Antigen (PSMA) assay. Prostate Specific Antigen (PSA) levels had already been determined. This provided an opportunity to see what correlations existed between the serum markers and the ProstaScint scan. A group of patients had the studies preprostatectomy, whereas another group had the studies postprostatectomy.
  
  
  METHODS
  The scan results, serum PSA, serum PSMA, and clinical data were separately analyzed. PSMA serum levels were determined by Western blot.
  
  
  RESULTS
  Preoperatively, radical prostatectomy patients showed a correlation between serum PSA or PSMA levels and the ProstaScint scan in the total group (n = 86), or in an untreated group (n = 38). Preoperatively, PSMA correlated with the pathological stage, whereas PSA correlated with the scan. Postoperatively, only PSMA serum levels correlated with the scan in an untreated group (n = 40).
  
  
  CONCLUSIONS
  Preoperatively or postoperatively, Western blot PSMA serum levels predict the stage of disease or local, regional, or distant metastases, as shown by ProstaScint scan. Both the scan and the serum tests provide prognostic information and evaluate the extent of disease to a more significant degree than previously possible.
authors.affiliation: Pacific Northwest Cancer Foundation/Northwest Hospital, Seattle, WA 98125-7001, USA.
authors.forename: G P
authors.initials: GP
authors.lastname: Murphy
authors.forename: R T
authors.initials: RT
authors.lastname: Maguire
authors.forename: B
authors.initials: B
authors.lastname: Rogers
authors.forename: A W
authors.initials: AW
authors.lastname: Partin
authors.forename: W B
authors.initials: WB
authors.lastname: Nelp
authors.forename: M J
authors.initials: MJ
authors.lastname: Troychak
authors.forename: H
authors.initials: H
authors.lastname: Ragde
authors.forename: G M
authors.initials: GM
authors.lastname: Kenny
authors.forename: R J
authors.initials: RJ
authors.lastname: Barren
authors.forename: V A
authors.initials: VA
authors.lastname: Bowes
authors.forename: A K
authors.initials: AK
authors.lastname: Gregorakis
authors.forename: E H
authors.initials: EH
authors.lastname: Holmes
authors.forename: A L
authors.initials: AL
authors.lastname: Boynton
mesh_terms: D000328:Adult; D000951:Antigens, Neoplasm / Q000097:blood*; D000954:Antigens, Surface / Q000097:blood*; D015153:Blotting, Western / Q000379:methods; D043425:Glutamate Carboxypeptidase II; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000097:blood* / Q000000981:diagnostic imaging* / Q000601:surgery; D011877:Radionuclide Imaging / Q000379:methods
chemical_list: D000951:Antigens, Neoplasm; D000954:Antigens, Surface; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II; D017430:Prostate-Specific Antigen